Comments to the National Medical Products Administration (NMPA) on the Provisions on Supervision and Administration of the Subject Responsibility for the Implementation of Drug Quality by Drug Marketing Authorisation Holders (Draft for Comments)

2022-12-09 | Beijing, Shanghai

On 9th December, European Chamber Pharmaceutical Working Group submitted comments to the National Medical Products Administration (NMPA) on the Provisions on Supervision and Administration of the Subject Responsibility for the Implementation of Drug Quality by Drug Marketing Authorisation Holders (MAH) (Draft for Comments). 

Member companies provided comments and suggestions regarding MAH responsibilities.